-+ 0.00%
-+ 0.00%
-+ 0.00%
Innovent's Zybrivo Receives Positive CHMP Opinion for First-Line Lung Cancer Treatment
Share
Listen to the news
Innovent's Zybrivo Receives Positive CHMP Opinion for First-Line Lung Cancer Treatment
  • Innovent Biologics' Zybrivo (sintilimab) received a positive CHMP opinion for first-line treatment of advanced non-squamous non-small cell lung cancer with chemotherapy.
  • European Commission marketing authorization remains pending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413125), on November 15, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending